LDS/Medical Tests/Methyl CpG Binding Protein 2 (MECP2) Gene Mutation Analysis, Rett Syndrome

Methyl CpG Binding Protein 2 (MECP2) Gene Mutation Analysis, Rett Syndrome

The MECP2 gene is located on the long (q) arm of the X chromosome at position 28 encodes methyl CpG binding protein 2 (MeCP2). MeCP2 protein has four functional domains: a methy binding domain (MBD), an RNA binding domain (arginine-glycine repeat RNA binding domain), a transcriptional repression domain (TRD), and an RNA splicing binding factor region (WW group II binding protein). MeCP2 interacts with a variety of chromatin remodeling complexes to establish a silent chromatin state at the methylated gene. The MeCP2 protein is highly expressed in neurons, and MeCP2-dependent gene regulation is important for proper neuronal maturation. Mutations in the MECP2 gene are the most common cause of Rett syndrome, a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females. These mutations include changes in single base pairs, insertions or deletions and changes that affect how the gene is transcribes to produce proteins. These mutations alter the structure of the MeCP2 protein or reduce the amount of protein that is produced. The resulting shortage of functional MeCP2 likely impairs the regulation of gene expression in neurons and may also disrupt alternative protein splicing critical for communication between cells. Mutations in MECP2 are associated with Rett, MECP2 duplication syndrome, MECP2-related severe neonatal encephalopathy, PPM-X syndrome and autism spectrum disorder.

Rett syndrome effects females and is characterized by repetitive movements such as hand clasping or wringing, motor dysfunction, intellectual disability, breathing problems, and autism symptoms. Girls with Rett syndrome appear normal for the first 6-18 months then enter a period of developmental stagnation followed by rapid regression in language and motor skills and then a long stable period.

An extra copy (duplication) of the MECP2 gene in each cell causes MECP2 duplication syndrome, a condition characterized by intellectual disability, delayed development, and seizures. Duplication of the MECP2 gene results in the production of extra MeCP2 protein and a subsequent increase in protein function. The resulting changes in gene regulation and protein production lead to abnormal neuronal function.

MECP2-related severe neonatal encephalopathy is the disorder seen most commonly in males with mutations of MECP2. It is a relentless neurodegenerative syndrome with abnormal tone, involuntary movements, severe seizures and breathing abnormalities. Death often occurs before two years of age. Less commonly males with mutations in MECP2 have a syndrome with moderate to severe intellectual disability, pyramidal signs, parkinsonism and macroorchidism (PPM-X). Mutations that cause PPM-X syndrome lead to the production of a MeCP2 protein that cannot properly interact with DNA or other proteins and so cannot control the expression of genes.

  • As an aid in diagnosis of Rett syndrome or other MECP2-related disorders such as MECP2 duplication syndrome, MECP2-related severe neonatal encephalopathy, PPM-X syndrome and autism spectrum disorder
  • For the prenatal diagnosis in at-risk pregnancies

Positive for known and published mutations (pathogenic variants) is consistent with a diagnosis of an MECP2-related disorder (e.g. Rett syndrome, variant or atypical Rett syndrome, or severe neonatal encephalopathy).

Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Sequence analysis by bidirectional sequence analysis gene-targeted deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole blood (EDTA), amniotic fluid, chorionic villus sample (CVS), buccal swab.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Multigene panel, MRI, Comprehensive epilepsy panel, Rett/Angelman syndrome panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Neuromolecular Med. 2014 Jun;16(2):231-64. [PMID: 24615633]
  • Adv Exp Med Biol. 2017;978:3-21. [PMID: 28523538]
  • J Clin Invest. 2015;125: 2914-23. [PMID: 26237041]
  • BMC Genet. 2015; 16:77. [PMID: 26148505]
  • Biochem Cell Biol. 2011;89: 1-11. [PMID: 21326358]
  • Curr Psychiatry Rep. 2010;12: 127-34. [PMID: 20425298]
  • Translational Neuroimaging, In chapter 9; Translational Neuroimaging for Drug Discovery and Development in Autism Spectrum Disorders, 2013: 245–280. doi:10.1016/b978-0-12-386945-6.00009-3
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/MECP2